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The title compound, C23H26F2N2O4, is a dipeptidic inhibitor of
 -secretase, one of the enzymes involved in Alzheimer’s dis-
ease. The molecule adopts a compact conformation, without
intramolecular hydrogen bonds. In the crystal structure, one of
the amide N atoms forms the only intermolecular N—H   O
hydrogen bond; the second amide N atom does not form
hydrogen bonds. High-resolution synchrotron diffraction data
permitted the unequivocal location and reﬁnement without
restraints of all H atoms, and the identiﬁcation of the
characteristic shift of the amide H atom engaged in the
hydrogen bond from its ideal position, resulting in a more
linear hydrogen bond. Signiﬁcant residual densities for
bonding electrons were revealed after the usual SHELXL
reﬁnement, and modeling of these features as additional
interatomic scatterers (IAS) using the program PHENIX led
to a signiﬁcant decrease in the R factor from 0.0411 to 0.0325
and diminished the r.m.s. deviation level of noise in the ﬁnal
difference Fourier map from 0.063 to 0.037 e A ˚  3.
Comment
Alzheimer’s disease, a progressive neurodegenerative dis-
order, is the most prominent contributor to senile dementia, a
condition affecting millions of individuals worldwide. The
disease is associated with the presence of extracellular plaques
and intracellular neuroﬁbrillary tangles in the brains of
Alzheimer’s sufferers (Goedert & Spillantini, 2006). Amyloid-
  plaque peptides are produced as a result of the sequential
proteolytic cleavages of a protein precursor, involving  - and
 -secretase enzymes (Chapman et al., 2001). A great amount
of effort has been expended in exploring the use of the
enzyme inhibitors and modulators aimed at preventing
amyloid formation (Wolfe, 2008). An approach based on
targeting  -secretase (Roberts, 2002; Barten et al., 2006;
Tomita, 2008) seems to be more promising (Wolfe, 2008) than
an approach that has been focused on  -secretase (Vassar,
2002; Schmidt et al., 2006). This research generated a number
of potent and speciﬁc inhibitors, among them N-[N-(3,5-
diﬂuorophenylacetyl)-S-alanyl]-(S)-phenylglycine tert-butyl
ester (DAPT) (Dovey et al., 2001). DAPT, (I), has been shown
to block amyloid-  production in human neuronal cultures,
and its administration to transgenic mice resulted in the ﬁrst
successful reduction of amyloid level in vivo (Dovey et al.,
2001; Lanz et al., 2003). Presenilin, a component of the
 -secretase complex, has been reported as a molecular target
of DAPT (Morohashi et al., 2006). Besides being a  -secretase
inhibitor, DAPT is also an inhibitor of the Notch signaling
pathway, involved in cell proliferation, differentiation and
apoptosis (Hansson et al., 2004; Katoh & Katoh, 2007). Due to
this inhibition property, future clinical applications of DAPT
for Alzheimer’s disease treatment are rather unlikely.
However, it is still widely used as a valuable tool in a variety of
biomedical investigations (Sjolund et al., 2008; Bittner et al.,
2009; Huang et al., 2010; Zhu et al., 2010), with new and
interesting features and possible novel applications emerging
(Grottkau et al., 2009; Loane et al., 2009). To facilitate the
rational design of  -secretase inhibitors with improved prop-
erties, we have crystallized and elucidated the structure of
DAPT.
The single molecule of the DAPT dipeptide in the asym-
metric unit of (I) is in a compact conformation (Fig. 1), in
which the main-chain torsion angles lie in the allowed regions
of the Ramachandran plot, viz. ’ =  69.43 (17)  and   =
 33.53 (18)  for Ala, and ’ =  161.83 (14)  and   =
157.57 (13)  for PheGly, so that the former residue corre-
sponds to the  -helical and the latter to the extended
 -conformation.
There is only a single intermolecular hydrogen bond
between the Ala N20—H group and carbonyl atom O21 of the
Ala residue related by translation parallel to a (Fig. 2a). The
remaining N and O atoms of DAPT are not engaged in
hydrogen bonds.
All H atoms were identiﬁed from the difference Fourier
synthesis. Two modes of their reﬁnement were applied, ﬁrstly
using the customary ‘riding’ model in geometrically idealized
positions utilizing the appropriate rigid-body constraints in
SHELXL (Sheldrick, 2008), and secondly reﬁning all their
organic compounds
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or restraints. The R(all) factors for such constrained and free
reﬁnements were comparable (0.0408 and 0.0399, respec-
tively). The root-mean-square deviation (r.m.s.d.) of all 26
bond lengths to all H atoms between the two models was
0.036 A ˚ and the r.m.s.d. of all bond directions was 4.0 , with
only one outlier differing by 14.6  from the idealized bond
direction. The single outlier corresponds to H201, an H atom
of the amide N atom, which is engaged in the only (inter-
molecular) hydrogen bond in the structure. Its distortion from
the direction exactly bisecting the C11—N20—C22 angle is
clearly caused by the tendency of the hydrogen bond to be
linear (Fig. 2b). Excluding it from the statistics of the bond
directions resulted in an r.m.s.d. for the 25 bond directions of
2.8 . The model after the nonconstrained reﬁnement of H
atoms was accepted as the result of the SHELXL minimiza-
tion.
The difference Fourier synthesis computed at the end of the
SHELXL reﬁnement showed relatively strong residual elec-
tron-density maxima located between bonded atoms (near
bond centers) for almost all bonds. These features are due to
bonding effects and their visibility is warranted by the
combination of three facts: high data resolution, high model
quality (low R factor) and low B factors (B <5A ˚ 2) (Afonine et
al., 2004). A multipolar model (Hansen & Coppens, 1978) is
appropriate to use in such cases, since it accounts for the
effects of atom interations. It has been demonstrated that a
simpliﬁed interatomic scatterers (IAS) model is capable of
producing results of similar quality using fewer reﬁnable
parameters (Afonine et al., 2004, 2007). An additional
reﬁnement was therefore undertaken with the program
PHENIX (Afonine et al., 2005), which supports reﬁnement
with the IAS option.
The PHENIX procedure started with the independent atom
model (IAM), which included completely unrestrained
reﬁnement of atomic coordinates, anisotropic displacement
parameters for non-H atoms and isotropic displacement
parameters for H atoms. The occupancies of the H atoms were
allowed to reﬁne, to account for the possible effect of H-atom
abstraction due to radiation damage (Meents et al., 2009). This
resulted in R(all) = 0.0411. For comparison, an analogous
organic compounds
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Figure 2
(a) The packing of DAPT molecules, viewed along the b direction. The
only intermolecular hydrogen bond is marked as dashed lines. (b)A
close-up of the N20—H   O21 hydrogen bond, with atom H210 shown in
two options, viz. in the calculated idealized position and after free
reﬁnement without constraints. The atom labeled O21 is a symmetry
equivalent generated from atom O21 by the operator (1 + x, y, z). The
difference map computed with atom H210 omitted from the structure-
factor calculation is shown as a wire mesh.
Figure 1
The molecule of DAPT, showing the atom-labeling scheme. Displacement
ellipsoids are drawn at the 50% probability level.reﬁnement was attempted where the only difference was that a
riding model (of the same character as previously with
SHELXL) was used for the H atoms instead of reﬁning them
freely. Reﬁnement using a riding model resulted in an
increased R(all) value of 0.0444. The model-phased residual
(Fobs   Fcalc) map computed for the best IAM model (with H
atoms reﬁned freely) showed signiﬁcant positive electron-
density peaks around covalent bond centers for almost all
bonds, as well as negative stick-like electron-density blobs at
the centers of the aromatic rings oriented perpendicular to the
ring plane (Fig. 3a). These features were accounted for by the
addition of IAS to those bonds that showed pronounced
residual electron density, and their occupancies and isotropic
displacement parameters were reﬁned (anisotropic displace-
ment parameters were reﬁned for aromatic ring-centered
IAS). This procedure resulted in R(all) = 0.0325 and consid-
erably cleared up the difference density map (Fig. 3b). The
distribution of the values of the grid points of this map is
shown in Fig. 4. Before the introduction of IAS, the map
values ranged between  0.214 and 0.266 eA ˚  3 (r.m.s.d. =
0.063 e A ˚  3), and afterwards the map was ﬂatter with a range
of values between  0.155 and 0.154 e A ˚  3 (r.m.s.d. =
0.037 e A ˚  3). The results of the PHENIX reﬁnement should
be treated as ﬁnal, but are presented in the Supplementary
Material, since the reﬁned parameters are not accompanied by
standard uncertainties.
Experimental
DAPT was prepared according to the general synthetic procedure
reported by Kan et al. (2004), and a 64% overall yield was obtained.
The crude product was puriﬁed using preparative high-pressure
liquid chromatography, followed by crystallization from a 1:1 mixture
of acetonitrile and water.
A needle-like crystal of (I) elongated along a was selected, picked
up in a rayon loop and quickly cryo-cooled in a stream of cold
nitrogen gas at the single-axis goniostat of the SERCAT synchrotron
station 22ID at the Advanced Photon Source, Argonne National
Laboratory, USA. Diffraction images were collected using a Mar-
research MAR300 CCD detector in four passes differing in their
effective exposure and resolution limits, in order to measure
adequately the weakest high-resolution reﬂections as well as the
strongest low-angle reﬂections without overloading the detector
organic compounds
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Figure 3
(a) Difference Fourier map at 0.11/ 0.15 e A ˚  3 contour levels (in the
electronic version of the paper, blue denotes positive and red negative)
before modeling interatomic scatterers in PHENIX.( b) Difference
Fourier map after IAS reﬁnement at the same contour levels. The
positions of the interatomic scatterers (at the centers of the bonds and
phenyl rings) are marked as spheres of arbitrary radii, in addition to all
atoms.
Figure 4
The distribution of the values of the residual difference map before
(upper curve) and after (lower curve) the introduction of IAS into the
reﬁned model. The graph shows the fraction of map grid points within ten
ranges of the density values in the whole map.pixels. All 53285 measured intensities from all passes were scaled and
merged together into the set of 3216 unique reﬂections with an
overall Rmerge factor of 0.061. The data set is rather strong, with an I/
 (I) ratio of 38 at the highest resolution of 0.72 A ˚ .
Crystal data
C23H26F2N2O4
Mr = 432.46
Orthorhombic, P212121
a = 5.490 (5) A ˚
b = 15.720 (15) A ˚
c = 24.82 (2) A ˚
V = 2142 (4) A ˚ 3
Z =4
Synchrotron radiation
  = 0.70000 A ˚
  = 0.10 mm
 1
T = 100 K
0.25   0.05   0.04 mm
Data collection
Marresearch MAR300 CCD
diffractometer
Absorption correction: multi-scan
(SCALEPACK; Otwinowski
et al., 2003)
Tmin = 0.974, Tmax = 0.996
3216 measured reﬂections
3216 independent reﬂections
3157 reﬂections with I >2  (I)
Rint = 0.061
Reﬁnement
R[F
2 >2  (F
2)] = 0.040
wR(F
2) = 0.112
S = 1.10
3216 reﬂections
384 parameters
All H-atom parameters reﬁned
 max = 0.35 e A ˚  3
 min =  0.23 e A ˚  3
The H atoms were located in a difference synthesis and reﬁned
without restraints.
The PHENIX (Afonine et al., 2005) reﬁnement was performed
using a direct summation algorithm for structure-factor and gradient
calculation (as opposed to using a fast Fourier transform) and using a
maximum-likelihood reﬁnement target (Lunin et al., 2002). Waas-
maier &Kirfel (1995) approximation to the standard form factors was
used. The form factors for IAS are distributed as part of cctbx
(Grosse-Kunstleve et al., 2002).
Data collection: SERGUI (SERCATAPS beamline software); cell
reﬁnement: HKL-2000 (Otwinowski & Minor, 1997); data reduction:
HKL-2000; program(s) used to solve structure: SHELXD (Sheldrick,
2008); program(s) used to reﬁne structure: SHELXL97 (Sheldrick,
2008); molecular graphics: ORTEP-3 (Farrugia, 1997) and pyMOL
(DeLano, 2002); software used to prepare material for publication:
ORTEP-3 and pyMOL.
Richard Gildea and Luc Bourhis are thanked for their help
with using smtbx tools. This work was funded in part with
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Supplementary data for this paper are available from the IUCr electronic
archives (Reference: MX3037). Services for accessing these data are
described at the back of the journal.
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Table 1
Hydrogen-bond geometry (A ˚ ,  ).
D—H   AD —H H   AD    AD —H   A
N20—H201   O21
i 0.92 (4) 2.03 (3) 2.933 (3) 165 (3)
Symmetry code: (i) x þ 1;y;z.